AZN Earnings: Drugs Giant AstraZeneca (AZN) Zooms Higher on Cancer-Fighting Demand
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Forecast Beaters
The company reported that Q2 earnings per share beat forecasts, coming in at $2.17, up from $1.98 in the same period last year.
Revenues for the period also beat forecasts, soaring to a record $14.46 billion from $12.94 billion last time.
AstraZeneca said its 'broad and diverse pipeline' of drugs had helped with oncology sales doing particularly well, rising 18% to $6.3 billion. It was boosted by sales of its lung cancer drug Tagrisso and chemotherapy drug Enhertu, and continues to lead overall performance.
European sales were up 12% to $3 billion, with Chinese demand up 5% to nearly $2 billion.
U.S. revenue was up 13% to a record $6.32 billion. The pharmaceutical company is targeting 50% of its total revenue coming from the country by 2030, up from 44% in the second quarter.
To help that aim, the group has already committed to investing $50 billion in the U.S. by 2030 including a new manufacturing center in Virginia.
Tariff Uncertainty
That move was partly in response to uncertainty about the impact of President Trump's tariffs on the pharmaceutical sector.
AstraZeneca said that global trade uncertainty and pricing pressures still existed but it reiterated its full-year forecast. This should see total revenue increasing by a 'high single-digit percentage' and core earnings per share by a 'low double-digit' percentage.
Chief executive Sir Pascal Soriot said: 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key phase III trial readouts including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks.'
The group is known as a strong income investing stock. It further cheered investors by hiking its Interim dividend by 3% to $1.03.
Is AZN a Good Stock to Buy Now?
On TipRanks, AZN has a Strong Buy consensus based on 4 Buy ratings. Its highest price target is $97. AZN stock's consensus price target is $97, implying a 36.04% upside.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Economists Flip To Trump's Side After Jobs Data–And Jerome Powell Is Now In Trouble
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Just two days after Fed Chair Jerome Powell refused to pre-commit to a September rate cut, the U.S. labor market did it for him. SPY ETF breaks past support. See real-time price here. A weak July jobs report and the biggest downward 2-month revisions since 2020 have economists—and markets—racing to President Donald Trump's side on calling for lower interest rates. Labor Data Breaks Down And Manufacturing Is Not Helping Either The U.S. economy added just 73,000 jobs in July, far below the 110,000 expected. But the real shock came from the Bureau of Labor Statistics revising May and June non-farm payrolls down by a combined 258,000—erasing what were thought to be solid job gains. This is the largest two-month revision since the COVID-19 shock in 2020. Trending: Be part of the breakthrough that could replace plastic as we know it— Private-sector job growth was narrowly concentrated, driven largely by healthcare, while government payrolls fell by 10,000. The unemployment rate edged up to 4.2%, reversing June's drop. Wages, however, remained hot. Average hourly earnings rose 0.3% month-over-month and 3.9% year-over-year, both beating forecasts. Still, signs of underlying weakness in the labor force—especially due to declining immigration—are mounting. Meanwhile, U.S. manufacturing continues to struggle, signaling ongoing headwinds from tariff-driven uncertainty. The ISM Manufacturing PMI decreased to 48 in July 2025, down from 49 in June and below the expected level of 49.5. It marked the fifth straight month of contraction and the lowest reading since October 2024. Wall Street Moves To The Dovish Side Markets are now fully pricing in two rate cuts by December, with the chance of a September 25-basis-point cut surging to 76% Friday, more than double Thursday's odds. Oxford Economics' Nancy Vanden Houten said the weak July report and historic revisions "raise the odds of a Fed rate cut in September." She warned that slower labor force growth, especially among foreign-born workers, may mask deeper structural issues."The foreign-born labor force has shrunk by 1.2 million in just six months," she said, linking the decline to the Trump administration's immigration policies. "Powell's take on September not being a live meeting might be under revision as we speak," said BOK Financial's analyst Steve Wyett, citing the sharp downward revisions. David Russell, analyst at TradeStation, indicated that "huge negative revisions undermine beliefs about the strength of the labor market," but warned that "there are still signs of stagflation, with hourly earnings up more than expected." Jamie Cox, managing partner for Harris Financial Group, weighed in. "Powell is going to regret holding rates steady this week. September is a lock for a rate cut—and it might even be 50 basis points." Bill Adams, chief economist at Comerica Bank, struck a more cautious tone. He said the weak July jobs report adds pressure on the Fed to cut rates later this year, but warned the decision "isn't a slam dunk." Adams said the Fed will closely watch the August jobs report and inflation data before making its next move. Yields on two-year Treasury bonds, which are highly sensitive to interest-rate expectations, tumbled 22 basis points to 3.75%, eyeing the largest intraday drop since August 2024. The U.S. dollar index – as closely tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:UUP) – fell 1.2% by 10:30 a.m. in New York, trimming weekly gains. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Arrived Home's Private Credit Fund's has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Photo: Shutterstock This article Economists Flip To Trump's Side After Jobs Data–And Jerome Powell Is Now In Trouble originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Should You Investigate Iress Limited (ASX:IRE) At AU$7.96?
Iress Limited (ASX:IRE), is not the largest company out there, but it saw significant share price movement during recent months on the ASX, rising to highs of AU$8.66 and falling to the lows of AU$7.42. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Iress' current trading price of AU$7.96 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Iress's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Is Iress Still Cheap? The stock seems fairly valued at the moment according to our valuation model. It's trading around 1.38% above our intrinsic value, which means if you buy Iress today, you'd be paying a relatively fair price for it. And if you believe that the stock is really worth A$7.85, there's only an insignificant downside when the price falls to its real value. So, is there another chance to buy low in the future? Given that Iress's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. View our latest analysis for Iress Can we expect growth from Iress? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with a negative profit growth of -11% expected over the next couple of years, near-term growth certainly doesn't appear to be a driver for a buy decision for Iress. This certainty tips the risk-return scale towards higher risk. What This Means For You Are you a shareholder? Currently, IRE appears to be trading around its fair value, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. Is your current exposure to the stock optimal for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on the stock, take a look at whether its fundamentals have changed. Are you a potential investor? If you've been keeping an eye on IRE for a while, now may not be the most advantageous time to buy, given it is trading around its fair value. The stock appears to be trading at fair value, which means there's less benefit from mispricing. In addition to this, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven't considered today, which can help crystalize your views on IRE should the price fluctuate below its true value. If you want to dive deeper into Iress, you'd also look into what risks it is currently facing. Case in point: We've spotted 1 warning sign for Iress you should be aware of. If you are no longer interested in Iress, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Higher Sugar Output in Brazil Weighs on Prices
October NY world sugar #11 (SBV25) on Thursday closed down -0.10 (-0.61%), and October London ICE white sugar #5 (SWV25) closed down -2.20 (-0.47%). Sugar prices settled lower on Thursday, with London sugar posting a 1-week low. Signs of stronger global sugar production in Brazil are weighing on sugar prices after Unica reported Brazil's Center-South sugar output in the first half of July rose +15% y/y to 3.4 MMT. Also, the amount of sugarcane being crushed for sugar by Brazil's sugar mills has increased to 54% from 50% the same time last year. More News from Barchart Reduced Tariff Risks Weigh on Arabica Coffee Arabica Coffee Slips as Brazil Tariff Fears Ease Dollar Strength Undercuts NY Cocoa Prices Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! The outlook for higher sugar production in Brazil is bearish for sugar prices. Datagro said Monday that dry weather in Brazil has encouraged the country's sugar mills to increase their cane crushing, diverting more of the cane crush toward more profitable sugar production rather than ethanol. Last Wednesday, sugar prices fell to 3-week lows after Bloomberg reported that India may permit local sugar mills to export sugar in the next season, which starts in October, as abundant monsoon rains may produce a bumper sugar crop. India's Meteorological Department reported Monday that cumulative monsoon rain in India is at 440.1 mm, or 8% above normal as of July 27. Also, the Indian Sugar and Bio-energy Manufacturers Association on Thursday said that it will seek permission to export 2 MMT of sugar in 2025/26. The outlook for higher sugar production in India, the world's second-largest producer, is bearish for prices. On June 2, India's National Federation of Cooperative Sugar Factories projected that India's 2025/26 sugar production would climb +19% y/y to 35 MMT, citing larger planted cane acreage. That would follow a -17.5% y/y decline in India's sugar production in 2024/25 to a 5-year low of 26.2 MMT, according to the Indian Sugar Mills Association (ISMA). Sugar prices have retreated over the past three months, with NY sugar falling to a 4.25-year low earlier this month and London sugar sliding to a nearly 4-year low, driven by expectations of a sugar surplus in the 2025/26 season. On June 30, commodities trader Czarnikow projected a 7.5 MMT global sugar surplus for the 2025/26 season, the largest surplus in 8 years. On May 22, the USDA, in its biannual report, projected that global 2025/26 sugar production would increase by +4.7% y/y to a record 189.318 MMT, with global sugar ending stocks at 41.188 MMT, up 7.5% y/y. Signs that the recent slide in sugar prices to 4-year lows has sparked a pickup in demand are positive for sugar prices. China's June sugar imports soared by 1,435% to 420,000 MT. Also, President Trump last Wednesday said Coca-Cola agreed to use cane sugar in Coke beverages sold in the US instead of high-fructose corn syrup, which could boost US sugar consumption by +4.4% to 11.5 MMT from 11 MMT currently, according to Bloomberg Intelligence. Sugar prices also have support from reduced sugar production in Brazil. Unica reported Thursday that the cumulative 2025/26 Brazil Center-South sugar output through mid-July fell by -9.2% y/y to 15.655 MMT. Last month, Conab, Brazil's government crop forecasting agency, said 2024/25 Brazil sugar production fell by -3.4% y/y to 44.118 MMT, citing lower sugarcane yields due to drought and excessive heat. The outlook for higher sugar production in Thailand is bearish for sugar prices. On May 2, Thailand's Office of the Cane and Sugar Board reported that Thailand's 2024/25 sugar production rose +14% y/y to 10.00 MMT. Thailand is the world's third-largest sugar producer and the second-largest exporter of sugar. The International Sugar Organization (ISO) raised its 2024/25 global sugar deficit forecast to a 9-year high of -5.47 MMT on May 15, up from a February forecast of -4.88 MMT. This indicates a tightening market following the 2023/24 global sugar surplus of 1.31 MMT. ISO also cut its 2024/25 global sugar production forecast to 174.8 MMT from a February forecast of 175.5 MMT. The USDA, in its bi-annual report released May 22, projected that global 2025/26 sugar production would climb +4.7% y/y to a record 189.318 MMT and that global 2025/26 human sugar consumption would increase +1.4% y/y to a record 177.921 MMT. The USDA also forecasted that 2025/26 global sugar ending stocks would climb +7.5% y/y to 41.188 MMT. The USDA's Foreign Agricultural Service (FAS) predicted that Brazil's 2025/26 sugar production would rise +2.3% y/y to a record 44.7 MMT FAS predicted that India's 2025/26 sugar production would rise +25% y/y to 35.3 MMT due to favorable monsoon rains and increased sugar acreage. FAS predicted that Thailand's 2025/26 sugar production will climb +2% y/y to 10.3 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
